Profile data is unavailable for this security.
About the company
Lotus Pharmaceutical Co Ltd is a Taiwan-based company mainly engaged in the manufacture and sale of generic drugs. The products are mainly solid preparations such as tablets and capsules. The main products include oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs and mental disease drugs. The Company is also engaged in the drug research, development and clinical testing business, as well as the product licensing business. The Company mainly distributes products in Taiwan, South Korea, the United States, China mainland, Japan, Europe and Southeast Asia markets.
- Revenue in TWD (TTM)17.59bn
- Net income in TWD4.33bn
- Incorporated1966
- Employees1.10k
- LocationLotus Pharmaceutical Co Ltd17FNo. 277, Songren Road, Xinyi DistrictTAIPEI 110TaiwanTWN
- Phone+886 227005908
- Fax+886 227008286
- Websitehttps://www.lotuspharm.com.tw/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ScinoPharm Taiwan Ltd | 3.43bn | 403.00m | 18.42bn | 1.01k | 45.83 | 1.78 | 21.07 | 5.37 | 0.5084 | 0.5084 | 4.33 | 13.12 | 0.2871 | 1.27 | 6.63 | -- | 3.37 | 2.33 | 3.69 | 2.51 | 38.89 | 41.09 | 11.76 | 9.10 | 5.00 | -- | 0.0592 | 109.25 | -2.39 | -2.00 | -18.73 | -8.31 | 16.90 | -9.35 |
| Lotus Pharmaceutical Co Ltd | 17.59bn | 4.33bn | 74.78bn | 1.10k | 17.09 | 3.69 | 13.33 | 4.25 | 16.47 | 16.47 | 66.89 | 76.24 | 0.5014 | 1.94 | 2.58 | -- | 12.35 | 9.17 | 15.04 | 11.36 | 56.39 | 49.32 | 24.63 | 15.99 | 1.89 | -- | 0.3809 | 26.77 | 15.89 | 21.41 | 35.91 | 110.44 | 52.35 | -- |
| Bora Pharmaceuticals Co Ltd | 14.17bn | 3.19bn | 80.04bn | 91.00 | 25.36 | 8.17 | 19.70 | 5.65 | 30.64 | 30.64 | 134.98 | 95.05 | 0.4418 | 2.12 | 2.16 | -- | 10.25 | 11.27 | 21.59 | 18.66 | 47.99 | 39.25 | 23.19 | 18.55 | 0.9497 | 5.53 | 0.6005 | 37.82 | 35.31 | 59.57 | 117.70 | 46.91 | 128.20 | 64.83 |
Data as of Nov 14 2024. Currency figures normalised to Lotus Pharmaceutical Co Ltd's reporting currency: Taiwan Dollar TWD
6.56%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 02 Oct 2024 | 5.01m | 1.89% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 2.35m | 0.88% |
| Capital Investment Trust Corp.as of 30 Sep 2024 | 2.18m | 0.82% |
| Uni-President Asset Management Corp.as of 30 Sep 2024 | 1.97m | 0.74% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 1.38m | 0.52% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 1.36m | 0.51% |
| Lazard Asset Management LLCas of 31 Mar 2024 | 1.31m | 0.49% |
| Fubon Asset Management Co., Ltd.as of 01 Oct 2024 | 981.00k | 0.37% |
| Yuanta Securities Investment Trust Co., Ltd.as of 04 Oct 2024 | 511.79k | 0.19% |
| BlackRock Advisors (UK) Ltd.as of 03 Oct 2024 | 376.31k | 0.14% |
More ▼
Data from 30 Jun 2024 - 08 Nov 2024Source: FactSet Research Systems Inc.
